AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01227967
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Trial: NCT00480857
Drug: Docetaxel (Taxotere)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
Trial: NCT02781792
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Given standard of care
Trial: NCT00092144
Drug: MK0476, montelukast sodium / Duration of Treatment: 4 weeks
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02831491
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02831491
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00651118
Drug: azelastine Hcl
RxNorm normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: azelastine Hcl 548 mcg
Trial: NCT04150289
Drug: Farydak
RxNorm normalized name: Farydak
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: non-interventional study
Trial: NCT00921115
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
Trial: NCT00921115
Drug: Anastrazole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
Trial: NCT01527045
Drug: Atorvastatin Calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01527045
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01527045
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01527045
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT00649285
Drug: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT01481350
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
Trial: NCT01696799
Drug: Econazole Nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03462641
Drug: Flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg in 10cc normal saline
Trial: NCT00651118
Drug: azelastineHcl / fluticasone propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
Trial: NCT01736423
Drug: YM060
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00606411
Drug: Topiramate or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
Trial: NCT00237666
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone 20-60 mg BID, taken orally.
Trial: NCT02443337
Drug: Necitumumab
RxNorm normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT00920361
Drug: Follitropin beta
RxNorm normalized name: Follitropin Beta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
Trial: NCT00002509
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002509
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002509
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03479450
Drug: surfactant
RxNorm normalized name: Surfactant
DrugBank: Recombinant surfactant protein D (DB18438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surfactant is given when neonatal respiratory distress syndrome is diagnosed
Trial: NCT02151903
Drug: DI-Leu16-IL2
RxNorm normalized name: di-isopropylammonium
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Trial: NCT01927406
Drug: Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
Trial: NCT01852942
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
Trial: NCT00874354
Drug: Intracoronary Transplantation of Bone Marrow Stem Cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
Trial: NCT02053181
Drug: Cadazolid
RxNorm normalized name: Cadazolid
DrugBank: Cadazolid (DB11847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
Trial: NCT00616460
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
Trial: NCT02635828
Drug: Palonosetron 0.075 mg IV
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Trial: NCT02635828
Drug: Dexamethasone 10 mg IV
RxNorm normalized name: dexamethasone phosphate 10 MG/ML
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Trial: NCT02635828
Drug: Promethazine 25 mg IV
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
Trial: NCT00308503
Drug: eplivanserin (SR46349)
RxNorm normalized name: Eplivanserin
DrugBank: Eplivanserin (DB12177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00712829
Drug: 123-I-MIP-1072
RxNorm normalized name: MIP-1095 I-123
DrugBank: MIP-1095 I-123 (DB12994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi intravenous injection given one time during the study
Trial: NCT00712829
Drug: 123-I-MIP-1095
RxNorm normalized name: MIP-1095 I-123
DrugBank: MIP-1095 I-123 (DB12994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mCi intravenous injection given one time during the study
Trial: NCT03054545
Drug: Iguratimod
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Iguratimod 25mg twice a day, oral administrated.
Trial: NCT00651118
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fluticasone propionate 200 mcg
Trial: NCT03679780
Drug: BQ-788
RxNorm normalized name: BQ-788
DrugBank: BQ-788 (DB17984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Trial: NCT03679780
Drug: BQ-123
RxNorm normalized name: BQ-123
DrugBank: BQ-123 (DB12054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Trial: NCT03679780
Drug: L-Arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
Trial: NCT03679780
Drug: Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
Trial: NCT03679780
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
Trial: NCT03852303
Drug: ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: evaluate effect of ivermectin on frequency of seizures
Trial: NCT02506855
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01881230
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Trial: NCT01881230
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Trial: NCT01881230
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Trial: NCT02232425
Drug: IX-01
RxNorm normalized name: Hematoporphyrin ix
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01012622
Drug: Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
Trial: NCT02631863
Drug: Aminolaevulinic acid
DrugBank: Laevulinic Acid (DB02239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminolaevulinic acid with illumination
Trial: NCT01047956
Drug: Methadone; NAC
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone NAC
Trial: NCT01047956
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methadone
Trial: NCT00006209
Drug: Tucaresol
RxNorm normalized name: Tucaresol
DrugBank: Tucaresol (DB13027)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01591291
Drug: Ondansetron + Brief Behavioral Enhancement Treatment
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 4ug/kg twice daily
Trial: NCT01160068
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Tablets 1000 mg
Trial: NCT01160068
Drug: Glucophage
RxNorm normalized name: Glucophage
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Glucophage 1000 mg tablets of Bristol-Myers Squibb
Trial: NCT03440515
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment for severe skin rash induced by imatinib
Trial: NCT01843166
Drug: Premarin vaginal cream
RxNorm normalized name: Premarin Vaginal Product
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g at bedtime twice weekly
Trial: NCT02201329
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (subcutaneous)
Trial: NCT02201329
Drug: Volasertib
RxNorm normalized name: Volasertib
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib escalating doses (intravenous)
Trial: NCT00625625
Drug: isosulfan blue
RxNorm normalized name: Isosulfan Blue
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01836536
Drug: Bevacizumab standard of care
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard treatment associated with circulating leucocytes (blood samplings)
Trial: NCT03860428
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the medical treatment arm the in-tention is to close the ductus arteriosus.
Trial: NCT02560337
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00078026
Drug: Apomine
RxNorm normalized name: Apomine
DrugBank: Apomine (DB12276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02198859
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03235921
Drug: Nitroglycerin patch 5mg
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
Trial: NCT01538576
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prescribed by the physicians as a result of normal clinical practice
Trial: NCT04916392
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
Trial: NCT02521038
Drug: Brilinta
RxNorm normalized name: Brilinta
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
Trial: NCT00633087
Drug: 2-deoxyglucose
RxNorm normalized name: 2-DEOXYGLUCOSE
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
Trial: NCT03715140
Drug: Crucumin
RxNorm normalized name: Cucumis melo extract
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of the effect of Crucumin in patients with osteoarthritis
Trial: NCT02799758
Drug: NK-104-CR
RxNorm normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-CR 8 mg for 52 weeks
Trial: NCT02799758
Drug: Placebo (for Livalo® IR)
RxNorm normalized name: Livalo
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Livalo® IR 4 mg placebo for 52 weeks
Trial: NCT00644969
Drug: varenicline (CP-526,555)
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
Trial: NCT00697515
Drug: LDX
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
Trial: NCT04073758
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparing effects of remifentanil versus dexmedetomidine
Trial: NCT02436759
Drug: RVL-1201
RxNorm normalized name: ALLANTOIN 5 g in 100 mL TOPICAL CREAM [RVLAIM SILICONE SCAR Cream]
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RVL-1201 Ophthalmic Solution 0.1%
Trial: NCT02292290
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
Trial: NCT02292290
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
Trial: NCT02292290
Drug: Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As per clinical guidelines for prescription
Trial: NCT03054857
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
Trial: NCT04405999
Drug: Bromhexine Hydrochloride
RxNorm normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
Trial: NCT01776788
Drug: insulin lispro injection, exenatide injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
Trial: NCT01776788
Drug: insulin lispro injection
RxNorm normalized name: Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
Trial: NCT00002546
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002546
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00491387
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
Trial: NCT00163475
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04231682
Drug: Denosumab Injection
RxNorm normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Trial: NCT02397421
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor